Renal Protein Phosphatase 2A Activity and Spontaneous Hypertension in Rats

Peiying Yu, Laureano D. Asico, Gilbert M. Eisner, Ulrich Hopfer, Robin A. Felder, Pedro A. Jose

Abstract—The impaired renal paracrine function of dopamine in spontaneously hypertensive rats (SHR) is caused by hyperphosphorylation and desensitization of the renal D1 dopamine receptor. Protein phosphatase 2A (PP2A) is critical in the regulation of G-protein–coupled receptor function. To determine whether PP2A expression and activity in the kidney are differentially regulated in genetic hypertension, we examined the effects of a D1-like agonist, fenoldopam, in renal cortical tubules and immortalized renal proximal tubule cells from normotensive Wistar-Kyoto rats (WKY) and SHR. In cortical tubules and immortalized proximal tubule cells, PP2A activity and expressions were greater in cytosol than in membrane fractions in both WKY and SHR. Although PP2A expressions were similar in WKY and SHR, basal PP2A activity was greater in immortalized proximal tubule cells of SHR than WKY. In immortalized proximal tubule cells of WKY, fenoldopam increased membrane PP2A activity and expression of the regulatory subunit PP2A-B56α, effects that were blocked by the D1-like antagonist SCH23390. Fenoldopam had no effect on cytosolic PP2A activity but decreased PP2A-B56α expression. In contrast, in immortalized proximal tubule cells of SHR, fenoldopam decreased PP2A activity in both membranes and cytosol but predominantly in the membrane fraction, without affecting PP2A-B56α expression; this effect was blocked by the D1-like antagonist SCH23390. We conclude that renal PP2A activity and expression are differentially regulated in WKY and SHR by D1-like receptors. A failure of D1-like agonists to increase PP2A activity in proximal tubule membranes may be a cause of the increased phosphorylation of the D1 receptor in the SHR. (Hypertension. 2000;36:1053-1058.)

Key Words: hypertension, genetic receptors, dopamine receptors, dopamine hypertension, essential phosphatase

E

Received June 22, 2000; first decision July 10, 2000; revision accepted July 17, 2000.

From the Departments of Pediatrics (P.Y., L.D.A., P.A.J.) and Physiology and Biophysics (P.A.J.), Georgetown University School of Medicine, Washington, DC; the Department of Internal Medicine (G.M.E.), Washington Hospital Center, Washington, DC; the Department of Physiology (U.H.), Case Western Reserve School of Medicine, Cleveland, Ohio; and the Department of Pathology and Medical Automation Research Center (R.A.F.), Charlottesville, Va.
Correspondence to Peiying Yu, MD, Department of Pediatrics, PHC-2, Georgetown University Medical Center, 3800 Reservoir Rd NW, Washington, DC 20007. E-mail yuyp@gunet.georgetown.edu

© 2000 American Heart Association, Inc.

Hypertension is available at http://www.hypertensionaha.org

1053
B′ or B56, and B′′ or PR72.16 B56 is a new gene family that encodes B56α, β, γ, δ, and ε proteins.17 The B56β and δ subunits are found predominantly in brain tissue, the B56α and γ subunits are most abundant in heart and muscle, and the ε subunit is expressed mainly in the testis, lung, and brain.17–20 Of the B56 isoforms, B56α appears to be the most abundantly expressed subunit in the kidney.17,19,21

PP2A activity and protein levels were examined in renal cortical tubules from spontaneously hypertensive rats (SHR) and their normotensive controls, Wistar-Kyoto rats (WKY). To eliminate any confounding influence of dopamine produced by renal proximal tubules from circulating l-dihydroxyphenylalanine (L-DOPA), studies were also performed in immortalized renal proximal tubule cells (RPTC)22; RPTC cannot synthesize dopamine in the absence of L-DOPA.23 Here we report that PP2A activity and expression of the PP2A regulatory subunit PP2A-B56α were differentially affected by D1-like receptor stimulation in the kidney of WKY and SHR.

**Methods**

**Materials**

Reagents were obtained from the following: monoclonal anti-human PP2A-B56α (Transduction Labs), polyclonal PP2A A subunits, Aα, and Aβ (Santa Cruz Biotech Inc); monoclonal anti-human PP2A catalytic subunit (PP2A-C) and Ser/Thr phosphatase Assay Kit (Upstate Biotech Inc),24 secondary antibodies for Western blots (Jackson ImmunoResearch Labs Inc), enhanced chemiluminescence Western blotting detection reagents (Amersham Corp), fenoldopam (Smith Kline Beecham Pharmaceuticals), and SCH23990 (RBI Inc).

**Renal Cortical Membranes**

Adult male WKY (body weight 375 ± 43 g, mean arterial pressure [MAP] 98 ± 3 mm Hg, n = 4) and SHR (body weight 307 ± 33 g, MAP 161 ± 3 mm Hg, n = 4) (Taconic Farms Inc), maintained on standard rat chow until the night before the experiment, were anesthetized with pentobarbital (50 mg/kg body wt IP) and tracheotomized (PE-240). MAP was monitored with Cardiomax II (Columbus Instruments). After a 30-minute equilibration period, saline or fenoldopam in saline (1 pmol/min per milligram of protein. The lower limit of detection was 20 pmol of Pi (released phosphate from the phosphopeptide).

**Immunoprecipitation and Immunoblotting**

The immunoprecipitation for the PP2A assay was performed by incubation of 50 to 200 μg of protein with 2 μg of PP2A-C monoclonal antibody and protein G beads in TBS buffer with rocking for 2 hours in a cold room. For immunoblotting, 50 to 100 μg of protein was loaded onto polyacrylamide gel. The amount of protein transferred onto the nitrocellulose membrane was verified by Ponceau-S stain. Immunoblotting and quantification of the immunoblots were performed as described previously with Quantiscan.26 The results were expressed as density units (DU).

**Preparation of Brush Border Membranes**

Brush border membranes (BBM) (100 μg/sample), prepared by MnCl2 precipitation and differential centrifugation,27 were treated with fenoldopam (5 μmol/L) or vehicle (saline) for 30 minutes at room temperature. The BBM were pelleted by centrifugation for 5 minutes, suspended in Laemmli buffer, and boiled for 5 minutes before immunoblotting.

**Immortalized RPTC and Subcellular Fractions**

Immortalized RPTC were maintained in DMEM/F12 supplemented with 5% fetal bovine serum, epidermal growth factor (10 ng/mL), insulin, transferrin, and selenium (5 μg/mL each) at 37°C in humidified 5% CO2/95% air.25 The cells were incubated for 1 hour in serum-free DMEM/F12 medium before agonist stimulation with the D1-like agonist fenoldopam (5 μmol/L). The cells were washed 3 times with TBS and disrupted by Dounce homogenizer or a syringe with a 27-gauge needle in TE buffer. The cell lysates were centrifuged at 2000 rpm for 5 minutes to remove the nuclear fraction. The supernatants were centrifuged at 14,000 rpm for 20 minutes and the resulting supernatant was taken to represent cytosol. The pellets were extracted for 30 minutes on ice with TBST lysis to obtain the membrane fractions.26 All experiments were carried out at 4°C in the presence of protease inhibitors described above. Protein concentrations were determined by the Bradford method.

**PP2A Activity Assay**

PP2A activity was measured after immunoprecipitation with anti-PP2A catalytic subunit antibody, according to Gupta et al28 with modifications. The cytosol and membrane preparations were subjected to immunoprecipitation carried out in triplicate (see below). The immune complexes with the protein G beads were initially washed twice with TBS buffer and finally washed with PP2A assay buffer (in mmol/L, 20 MOPS, pH 7.5, 60 2-mercaptoethanol, 100 NaCl, 0.1 mg/mL serum albumin). Immunoprecipitates with mouse IgG served as negative control. The immunoprecipitates were subjected to PP2A assay with a nonradioactive assay kit. In brief, the immune complexes containing PP2A were incubated for 20 minutes at 30°C in 30 μL of assay buffer containing 200 μmol/L of phosphopeptide (KRPTRRR). The reactions were terminated by putting the tubes on ice and immediately centrifuging at 8000 rpm for 1 minute. The supernatants (25 μL/well) were pipetted into 96-well microtiter plates containing malachite green solution (100 μL/well). The absorbance was measured at optical density of 630 nm after 15 minutes of development time. PP2A-specific activity was expressed as pmol/min per milligram of protein.

**Statistical Analysis**

The data are expressed as mean ± SEM. Comparison within groups was made by ANOVA for repeated measures (or paired t test when only 2 groups were compared), and comparison among groups (or t test when only 2 groups were compared) was made by ANOVA with Scheffe’s or Duncan’s test. Corresponding periods between 2 different groups were analyzed by independent t test. A value of P < 0.05 was considered significant.

**Results**

D1-like receptors are expressed to a greater extent in the renal cortex (proximal tubule, distal tubule, cortical collecting) and to a lesser extent in the medulla (medullary thick ascending limb of Henle). Therefore, PP2A expression and activity were studied in the renal cortex.

**In Vivo Studies**

**PP2A Expression**

**Basal Expression**

PP2A Aα, the structural subunit, PP2A-C, the catalytic subunit, and PP2A-B56α, the regulatory subunit, were expressed to a similar extent in renal cortical tubules of WKY and SHR (Figure 1). In agreement with data obtained with the use of tissues other than the kidney, PP2A was more abundant in the cytosol than in the particulate fraction.29 In WKY rats, PP2A...
to produce a greater natriuresis in WKY than in SHR.32 In the current experiments, fenoldopam infusion did dose-dependently by a PP2A inhibitor, okadaic acid (P < 0.05, n = 56.7 ± 6.5, 3.5 DU versus control, 44.0 ± 3.4 DU) (Figure 2). Results are expressed as mean ± SEM. Inset is one immunoblot from 4 independent experiments.

*Effect of D1-like agonist fenoldopam on B56α in renal BBM (100 μg each sample) from WKY and SHR. Fenoldopam decreased PP 2A-B56α in BBM of SHR (n = 4) and increased it in BBM from WKY (n = 8) (P < 0.05, ANOVA, Scheffe’s test) (for details of methods, see Reference 26).* Results are expressed as mean ± SEM.

**Basal Activity**

Basal PP 2A activity (pmol/min per milligram of protein) in WKY was 323 ± 97 in the cytosol and 252 ± 45 in the membrane fraction. The corresponding values in SHR were 385 ± 57 and 256 ± 38, respectively.

**Effect of D1-Like Agonist**

In WKY, the intrarenal arterial infusion of the D1-like agonist fenoldopam, for 10 or 30 minutes, produced no significant change in the cytosol. Fenoldopam also did not change PP 2A activity in renal membranes of WKY rats after 10 minutes but did increase it after 30 minutes (12.5 ± 5.0% from control) (P < 0.05 n = 4, ANOVA, Duncan’s test). In contrast, in SHR, fenoldopam decreased PP 2A activity in both renal cortical tubule cytosol (–17.1 ± 1.7% at 10 minutes, –17.1 ± 4.7% at 30 minutes) (P < 0.05 versus vehicle-treated rats) and renal cortical membrane (–14.8 ± 2.8% at 10 minutes, –16.7 ± 3.6% at 30 minutes, n = 4) (P < 0.05, ANOVA, Duncan’s test).

**In Vitro Studies**

We have reported that D1-like receptor function in immortalized RPTC is similar to that in renal proximal tubules freshly obtained from WKY.37,38 The uncoupling of the D1-like receptor in renal proximal tubules in SHR persists in immortalized RPTC from SHR.9,37,38 Thus, D1 receptor protein expression is similar in immortalized RPTC and renal proximal tubules from WKY and SHR.37,38 The D1-like receptor, specifically the D1 receptor subtype, is uncoupled from G protein subunits and effector proteins in immortalized RPTC and renal proximal tubules of WKY and SHR.37,38 Immortalized RPTC from WKY and SHR retain characteristics of renal proximal tubule cells,22 including expression of γ-glutamyl transpeptidase, a renal proximal tubule BBM marker. These cells express the two D1-like receptors, D1 and D1 receptors, G proteins, and Na+/H+ exchanger 3 protein to same extent in WKY and SHR.38

**PP2A Expression**

**Basal Expression**

As in the renal cortical tubules, in immortalized RPTC of WKY, PP 2A-B56α protein level was greater in cytosol (WKY, 41.5 ± 3.4 DU, n = 4) than in membrane fractions (WKY,
D1-like antagonist SCH23390. Results are expressed as on PP2A activity in RPTC from WKY and SHR. Cells were treated on B56 in membrane (\( \text{M} \)) of RPTC from WKY but did not change in E dependent manner; it slightly but significantly increased activity in cytosol (\( \text{F} \) figures, Scheffe’s test (vs baseline). C, Effect of D1-like antagonist PP# \( P \geq 0.05 \), ANOVA for repeated measures, SEM. #, \( P \leq 0.05 \), ANOVA for repeated measures, Scheffe’s test. PP2A activity in immunocomplexes were measured in immunoprecipitation. PP2A activity was measured in immunocomplexes were measured in immunoprecipitation. PP2A activity in membrane (\( \text{C} \)) of RPTC from WKY but did not change in cytosol (\( \text{D} \)) (n=4). Results are expressed as mean±SEM. \( \#P<0.05 \), WKY vs SHR; \( \*P<0.05 \), ANOVA for repeated measures, Scheffe’s test (vs baseline). C, Effect of D1-like agonist fenoldopam (5 \( \mu \text{mol/L} \)) on PP2A activity. Cells were treated with fenoldopam (5 \( \mu \text{mol/L} \)) and/or SCH23390 or vehicle (control) for 30 minutes at 37°C; cell preparations were subjected to immunoprecipitation. PP2A activity was measured in immuno-complexes. Fenoldopam increased PP2A activity in membrane of RPTC from WKY and decreased activity in cytosol of RPTC from SHR. Effect of fenoldopam on PP2A activity was blocked by D1-like antagonist SCH23390. Results are expressed as mean±SEM. \( \#P<0.05 \), \( \*P<0.05 \), ANOVA for repeated measures, ANOVA, Scheffe’s test.

Figure 3. A, Time course of effect of D1-like agonist fenoldopam on B56a protein expression in immortalized RPTC from WKY. B56a protein expression decreased in cytosol and increased in membrane of RPTC from WKY (n=4) rats in time-dependent manner. Data for SHR are not included because no changes were noted (n=3). Results are expressed as mean±SEM. \( \*P<0.05 \), ANOVA for repeated measures, Scheffe’s test (vs baseline). Inset is one immunoblot from 4 independent experiments. B, Time course of effect of D1-like agonist fenoldopam on PP2A activity in RPTC from WKY and SHR. Cells were treated with fenoldopam (5 \( \mu \text{mol/L} \)) or vehicle (control) for indicated time periods at 37°C; cell preparations were subjected to immunoprecipitation. PP2A activity in immunocomplexes were measured by nonradioactive kit and phosphopeptide as substrate (see Methods). Fenoldopam significantly decreased PP2A activity in cytosol (\( \text{H} \)) and membrane (\( \text{J} \)) of RPTC from SHR in time-dependent manner; it slightly but significantly increased activity in membrane (\( \text{C} \)) of RPTC from WKY but did not change in cytosol (\( \text{D} \)) (n=4). Results are expressed as mean±SEM. \( \#P<0.05 \), WKY vs SHR; \( \*P<0.05 \), ANOVA for repeated measures, Scheffe’s test (vs baseline). C, Effect of D1-like antagonist SCH23390 (5 \( \mu \text{mol/L} \)) on PP2A activity. Cells were treated with fenoldopam (5 \( \mu \text{mol/L} \)) and/or SCH23390 or vehicle (control) for 30 minutes at 37°C; cell preparations were subjected to immunoprecipitation. PP2A activity was measured in immunocomplexes. Fenoldopam increased PP2A activity in membrane of RPTC from WKY and decreased activity in cytosol of RPTC from SHR. Effect of fenoldopam on PP2A activity was blocked by D1-like antagonist SCH23390. Results are expressed as mean±SEM. \( \#P<0.05 \), \( \*P<0.05 \), ANOVA for repeated measures, ANOVA, Scheffe’s test.

PP2A Activity

Basal Activity

In the absence of endogenous dopamine, basal PP2A activity (pmol/min per milligram of protein) in the membrane was markedly higher in immortalized RPTC of SHR (540±54, n=4) than in immortalized RPTC of WKY (233±22, n=4) (\( P<0.05 \), t test). However, PP2A activity in cytosol was not different between SHR (496±51, n=4) and WKY (473±36, n=4).

Effect of D1-Like Agonist

In immortalized RPTC membranes from WKY, fenoldopam (5 \( \mu \text{mol/L} \)) increased PP2A activity (pmol/min per milligram of protein) with time, peaking at 30 minutes to 278±21 (\( P<0.05 \) versus basal activity, n=4); no effect was noted in cytosol (Figure 3B). In contrast, in the immortalized RPTC from SHR, fenoldopam decreased PP2A activity in both cytosol and membrane fractions in a time-dependent manner (Figure 3B), in agreement with studies that used renal cortical tubules. The maximum decrease occurred at 30 minutes down to 327±63 in membrane (n=3) and 428±30 in cytosol (n=3) (\( P<0.05 \) versus basal activity).

Effect of D1-Like Antagonist SCH23390

To determine if the effect of the D1 agonist fenoldopam is mediated by the occupation of the D1 receptor, studies were performed in the presence of the D1-like antagonist SCH23390 (5 \( \mu \text{mol/L} \)), a neutral antagonist. Fenoldopam (5 \( \mu \text{mol/L} \), 30 minutes (Figure 3C) increased PP2A activity in membrane of WKY (22.6±4.4% from basal) (\( P<0.05 \), n=4), which was blocked by SCH23390 (9.3±3.8% from basal, n=4); SCH23390, by itself (3.9±5.7% from basal, n=5), had no effect on PP2A activity. Fenoldopam decreased the activity in cytosol of SHR (−18.0±2.8% versus basal, n=4, \( P<0.05 \)), an effect that was blocked by SCH23390 (−10.4±4.3% from basal, n=4 \( P>0.05 \)); SCH23390, by itself, had no effect on PP2A activity (−8.7±3.6% from basal, n=4 to 5, \( P>0.05 \)).

Discussion

Several studies have shown that GRP plays a role in receptor dephosphorylation that is important in receptor resensitiza-
A high level of receptor phosphatase activity was reported to be associated with sequestered vesicular membranes, capable of dephosphorylating GRK-phosphorylated β-adrenergic receptors. Moreover, the resensitization of GPCR was inhibited by phosphatase inhibitors. GRP has been identified as a member of the family of PP2A. PP2A is generally considered as a cytosolic protein. However, PP2A is also expressed in cell particulate fractions. We also found that PP2A protein level was much higher in the cytosol than in membranes from renal cortex and immortalized RPTC in both WKY and SHR. However, PP2A specific activity was not different in cytosol and membrane fractions.

In addition to GPCR resensitization, PP2A is involved in a broad range of cellular processes, including signal transduction, intermediary metabolism, transcriptional regulation and control of DNA replication, and mitosis. The diversity of PP2A function is conferred by a variety of targeting/regulatory subunits. Each of the B subunits consists of numerous isoforms and splice variants. The PP2A regulatory B subunits have been found to have a number of functions, including targeting to distinct intracellular locations, determining substrate and tissue specificity, and acting as receptors of second messengers. Most of the B56 family members are phosphoproteins, and different isoforms have different targeting functions. The function of PP2A-B56α in hypertension remains to be determined. However, the failure of the D1-like agonist to translocate PP2A activity from cytosol to membrane in SHR may explain, in part, the “hyper-serine-phosphorylated D1 receptor in renal membranes in genetic hypertension.” The finding of a difference in PP2A activity between WKY and SHR in RPTC, where dopamine is absent, but not in renal cortical tubules, where dopamine is present, suggests that dopamine may tonically inhibit the PP2A activity, especially in the cytosol. Because PP2A-B56α is important in the targeting of the PP2A holoenzyme, a defect in B56α function could be involved in the pathogenesis of genetic hypertension. The important finding in our study is the remarkable difference in D1-like receptor-associated PP2A activity in RPTC membranes between WKY and SHR. The D1-like agonist fenoldopam increased membranous PP2A activity in WKY but decreased it in SHR. Fenoldopam translocated PP2A activity from cytosol to the membrane in WKY but not in SHR. We also found that the PP2A regulatory subunit B56α exists in the BBM, where most of the D1 receptors are located. It is of interest that PP2A-B56α protein level decreased in the BBM from SHR after fenoldopam treatment. The ability of the D1-like agonist to block both the increase in PP2A activity in WKY and the opposite response in SHR support the notion of an abnormality downstream of the D1-like receptor. Because there is no mutation of the D1 receptor in the SHR, this finding suggests that a primary abnormality of PP2A-B56α may be a cause of the discrepant response of SHR compared with WKY.

Activation of PP2A necessitates prior phosphorylation of the D1-like receptor. Presumably, activation of a G-protein–coupled receptor kinase (GRK) must have occurred after D1-like agonist stimulation. The phosphorylation of the D1 receptor by GRK by GRK2, GRK3, and GRK5 has been reported to play a role in the desensitization of the D1 receptor. Increased activity and expression of GRK2 has been reported to be constitutive in SHR. However, these changes occurred as a consequence of the hypertension. Because the increased phosphorylation of the D1 receptor in renal proximal tubules is ligand independent, the participation of a constitutively activated GRK must have occurred. The existence of this GRK was not determined in the current studies, but GRK6 has been reported to be constitutively activated. We speculate that a constitutively activated GRK (eg, GRK6) causes basal phosphorylation of D1-like receptors in renal proximal tubules in both WKY and SHR. D1-like agonist occupation further increases the phosphorylation of renal D1-like receptors in WKY but not in SHR. PP2A dephosphorylates and resensitizes renal D1-like receptors in WKY but not in SHR, resulting in a phosphorylated and desensitized D1-like receptor in genetic hypertension.

In conclusion, we have demonstrated that after D1-like agonist activation, PP2A activity in renal proximal tubules is increased in WKY but decreased in SHR. We speculate that the increased basal levels of serine-phosphorylated D1 receptor in RPTC in hypertension may be a consequence of a defect in dephosphorylation of the phosphorylated D1 receptor. Although we have demonstrated a role of PP2A in this response, the role of other phosphatases, for example, PP2B, in the desensitization of D1-like receptors in hypertension, remains to be determined.

Acknowledgments

This project was supported in part by grants from the National Heart, Lung, and Blood Institute (HL-23081, HL-62211, HL-58536) and National Institute of Diabetes, Digestive, and Kidney Diseases (DK-39308 and DK-52612).

References

1058 Hypertension December 2000


Renal Protein Phosphatase 2A Activity and Spontaneous Hypertension in Rats
Peiying Yu, Laureano D. Asico, Gilbert M. Eisner, Ulrich Hopfer, Robin A. Felder and Pedro A. Jose

Hypertension. 2000;36:1053-1058
doi: 10.1161/01.HYP.36.6.1053

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/36/6/1053

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/